In preclinical animal trials, third-party testing results showed that AIM Vaccine's mRNA RSV vaccine achieved significantly ...

RNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman ...

Discover how scientists developed a COVID-19 vaccine in record time using mRNA technology, leading to improved public health ...

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

With the triad of respiratory viruses present in our day-to-day, it is recommended that individuals receive both COVID-19, flu, and occasionally RSV and MPox vaccinations. However, there is a common ...

Consequently, Richter believes that Moderna is uncertain about the outlook of its Covid and RSV vaccines. The analyst cut her price target on MRNA to $51 from $99. A Potential Silver Lining for ...

Pfizer said it will 'support capacity-building initiatives, such as training healthcare professionals and advancing clinical ...

Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. MRNA has guided for 2025 revenues of $1.5B-$2.5B which doesn't seem to have ...

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA ... of respiratory syncytial virus (RSV), the recent approval of its RSV vaccine has ...